Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Corbus Pharmaceuticals ( (CRBP) ) has provided an announcement.
On May 15, 2025, Corbus Pharmaceuticals held its annual meeting where stockholders voted on the election of directors, the ratification of EisnerAmper LLP as the independent public accounting firm, and the approval of executive compensation. Additionally, Rachelle Jacques was appointed as Chair of the Board, succeeding Alan Holmer.
The most recent analyst rating on (CRBP) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases.
Average Trading Volume: 186,732
Technical Sentiment Signal: Sell
Current Market Cap: $89.82M
Find detailed analytics on CRBP stock on TipRanks’ Stock Analysis page.